

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10/530,176
Confirmation Number	8060
Filing Date	March 9, 2006
First Named Inventor	Graham Edmund KELLY
Art Unit	1612
Examiner Name	Benjamin J PACKARD
Attorney Docket Number	Q86664

## **U.S. PATENTS**

Examiner Initials*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## **U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initials*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1.	5-070348	JP	A	1993-03-23	KUREHA CHEMICAL IND CO LTD		Abstract

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	1.	H. ADLERCREUTZ, et al., "Determination of Urinary Lignans and Phytoestrogen Metabolites, Potential Antiestrogens and Anticarcinogens, In Urine of Women on Various Habitual Diets", Proceedings of the XII International Study Group for Steroid Hormones, (Rome, 2-4 December 1985), pages 791-797	
	2.	BEVERLY A. TEICHER, et al., "Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma", Cancer Chemother Pharmacol (1996) 38: 169-177	
	3.	SARA CALTAGIRONE, et al., "Flavonoids Apigenin and Quercetin Inhibit Melanoma Growth and Metastatic Potential", Int. J. Cancer: 87, (2000), pages 595-600	
	4.	HILARY J. CROSS, et al., "Effect of Quercetin on the Genotoxic Potential of Cisplatin", Int. J. Cancer: 66 (1996), pages 404-408	
	5.	JOHANN HOFMANN, et al., "Enhancement of the Antiproliferative Activity of Cis-Diamminedichloroplatinum(II) By Quercetin", Int. J. Cancer: 45, (1990), pages 536-539	
	6.	MORAG C.E. MCFADYEN, et al., "Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance", Biochemical Pharmacology 62 (2001), pages 207-212	
	7.	YASUYUKI SADZUKA, et al., "Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance", Toxicology Letter 114, (2000) pages 155-162	
	8.	AGNIESZKA SIWINSKA, et al., "Potentiation of the Antiproliferative Effect in Vitro of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D", Anticancer Research 21: (2001), pages 1925-1930	
	9.	JUSTYNA STAWINSKA, et al., "The reactivity of cis-platin. Spectroscopic properties of products isolated from the [cis-Pt(NH <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub> -quercetin] and [cis-Pt(NH <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub> -Cr <sup>VI</sup> -quercetin] systems," Transition Metal Chemistry 26: 2001, pages 153-159	

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.P./**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Not for submission under 37 CFR 1.99)	Application Number	10/530,176
	Confirmation Number	8060
	Filing Date	March 9, 2006
	First Named Inventor	Graham Edmund KELLY
	Art Unit	1612
	Examiner Name	Benjamin J PACKARD
	Attorney Docket Number	Q86664

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T <sup>5</sup>
	10.	YUICHIRO TAKEDA, et al, "Reversal of Multidrug Resistance By Tyrosine-Kinase Inhibitors in a Non-P-Glycoprotein-Mediated Multidrug-Resistant Cell Line", Int. J. Cancer: 57, (1994), pages 229-239	
	11.	ELZBIETA ZYNER, et al., "Platinum(II) and Palladium(II) N,O-Chelates With Substituted Flavanone Containing Ligands", Drug Research, Vol. 56, No. 2, 1999, pages 159-167	
	12.	Database Medline - XP008099672 & Am J Resp Cell 1997, 17, 51-59	

EXAMINER SIGNATURE			
Examiner Signature	/Benjamin Packard/	Date Considered	10/22/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.P./

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.